Last reviewed · How we verify
NCT05417048
Clinical Study of Glycosylated Extracellular Vesicles for Early Diagnosis of Breast Cancer
Status unknown
Last updated 23 February 2023
What this trial tests
trial testing Blood Sample in Breast Cancer in 420 participants. Status unknown.
Timeline
14 July 2022
Primary endpoint
15 December 2023
15 December 2023
15 June 2024
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 420 |
| Start date | 14 July 2022 |
| Primary completion | 15 December 2023 |
| Estimated completion | 15 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Blood Sample — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Peking University
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single-center, non-randomized, cohort study designed to evaluate the clinical diagnostic performance of glycosylated extracellular vesicles and their contents for early detection of breast cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression.
Lopez K, Lai SWT, Lopez Gonzalez EJ, Dávila RG, et al · · 2023 · cited 49× · PMID 37025182 · DOI 10.3389/fcell.2023.1154576 -
Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.
Tran HL, Zheng W, Issadore DA, Im H, et al · · 2025 · cited 25× · PMID 40720603 · DOI 10.1021/acsnano.5c00706 -
Influence of Extracellular Vesicles on Lung Stromal Cells during Breast Cancer Metastasis.
Patel U, Susman D, Allan AL. · · 2023 · cited 13× · PMID 37511559 · DOI 10.3390/ijms241411801 -
Extracellular Vesicles: Diagnostic and Therapeutic Applications in Cancer.
Di Bella MA, Taverna S. · · 2024 · cited 11× · PMID 39336143 · DOI 10.3390/biology13090716 -
Comparison Study of Small Extracellular Vesicle Isolation Methods for Profiling Protein Biomarkers in Breast Cancer Liquid Biopsies.
Lee Y, Ni J, Wasinger VC, Graham P, et al · · 2023 · cited 7× · PMID 37895140 · DOI 10.3390/ijms242015462 -
Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis.
Khan MS, Wong GL, Zhuang C, Najjar MK, et al · · 2024 · cited 5× · PMID 39175471 · DOI 10.3389/fonc.2024.1436942 -
Extracellular Vesicles in cancer: from isolation and characterization to metastasis, drug resistance, and clinical applications.
Jurj A, Paul D, Calin GA. · · 2025 · cited 4× · PMID 40629268 · DOI 10.1186/s12885-025-14375-7
Verify or expand the search:
- PubMed search for NCT05417048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood Sample
Trials testing the same drug.
- NCT06895681 — UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations · not yet recruiting
- NCT07148245 — Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma · recruiting
- NCT04789551 — T Cell Profiling in Patients with Multiple Sclerosis · not yet recruiting
- NCT06962995 — Multi-Cancer Detection Observational Cohort Study · recruiting
- NCT06861244 — Embryonal Tumor With Multilayered Rosettes · Phase 2 · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05417048 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 23 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing